AbbVie Gross Profit 2010-2024 | ABBV

AbbVie annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • AbbVie gross profit for the quarter ending March 31, 2024 was $8.216B, a 0.28% decline year-over-year.
  • AbbVie gross profit for the twelve months ending March 31, 2024 was $33.880B, a 13.99% decline year-over-year.
  • AbbVie annual gross profit for 2023 was $33.903B, a 16.58% decline from 2022.
  • AbbVie annual gross profit for 2022 was $40.64B, a 4.87% increase from 2021.
  • AbbVie annual gross profit for 2021 was $38.751B, a 27.4% increase from 2020.
AbbVie Annual Gross Profit
(Millions of US $)
2023 $33,903
2022 $40,640
2021 $38,751
2020 $30,417
2019 $25,827
2018 $25,035
2017 $21,174
2016 $19,806
2015 $18,359
2014 $15,534
2013 $14,209
2012 $13,872
2011 $12,805
2010 $11,345
2009 $10,158
AbbVie Quarterly Gross Profit
(Millions of US $)
2024-03-31 $8,216
2023-12-31 $8,597
2023-09-30 $7,442
2023-06-30 $9,625
2023-03-31 $8,239
2022-12-31 $10,951
2022-09-30 $9,790
2022-06-30 $10,413
2022-03-31 $9,486
2021-12-31 $10,566
2021-09-30 $9,952
2021-06-30 $9,436
2021-03-31 $8,797
2020-12-31 $9,174
2020-09-30 $7,852
2020-06-30 $6,714
2020-03-31 $6,677
2019-12-31 $6,698
2019-09-30 $6,559
2019-06-30 $6,436
2019-03-31 $6,134
2018-12-31 $6,283
2018-09-30 $6,401
2018-06-30 $6,344
2018-03-31 $6,007
2017-12-31 $5,458
2017-09-30 $5,379
2017-06-30 $5,415
2017-03-31 $4,922
2016-12-31 $5,242
2016-09-30 $4,928
2016-06-30 $5,047
2016-03-31 $4,589
2015-12-31 $4,925
2015-09-30 $4,777
2015-06-30 $4,559
2015-03-31 $4,098
2014-12-31 $4,333
2014-09-30 $3,925
2014-06-30 $3,813
2014-03-31 $3,463
2013-12-31 $3,829
2013-09-30 $3,566
2013-06-30 $3,638
2013-03-31 $3,176
2012-12-31 $3,941
2012-09-30 $3,494
2012-06-30 $3,420
2012-03-31 $3,017
2011-12-31 $1,432
2011-09-30 $4,409
2011-06-30 $4,274
2011-03-31 $2,689
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $302.599B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11